NEUTRAL / HOT-JOBS RATE RISK Friday's index decline was modest and small caps held up, but a large payroll upside surprise lifted Treasury yields and leaves expensive long-duration themes exposed to next week's inflation data.
Generated 08:30:35 CEST (Europe/Rome) / 06:30:35 UTC. Data cutoff 08:30 CEST. Cash, yields and thematic returns are Friday, Sep. 4 closes. It is Saturday: U.S., European and Asian cash markets are closed and Friday futures settlements are not live weekend indications. This report audits Friday's published calls without hindsight and maps the next 7–30 days.
Adjacent daily closes; Treasury rates are the official Sep. 4 par curve. WTI and gold use Yahoo's daily adjusted bars; the thin displayed gold-volume field makes the exact futures close lower-quality than the cash-index data. No Saturday futures signal is asserted.
August nonfarm payrolls rose 162,000 versus 53,000 expected; unemployment held at 4.1%, average hourly earnings rose 0.3% month/month and 3.1% year/year, and June/July were revised higher. CNBC reported FedWatch odds of a 25bp September hike at 58% Friday. CNBC/BLS recap · CME FedWatch
S&P, Nasdaq and Dow fell, but Russell gained. Within AI, VRT +4.35%, CRDO +3.90% and ORCL +3.08% contrasted with SNOW −5.41%, PLTR −4.49% and HPE −4.48%—evidence that earnings/event positioning mattered more than a single sector narrative. S&P · VRT
Nasdaq's live calendar now lists both ORCL and ADBE after the Sep. 10 close; this corrects yesterday's ORCL Sep. 8 listing. August CPI is scheduled Sep. 11, then FOMC/SEP Sep. 15–16. Cloud monetization and duration will be tested in sequence. Nasdaq calendar · BLS CPI · Fed
| Prior call | Friday evidence | Audit verdict | What changes now |
|---|---|---|---|
| NVDA conditional bullish Close confirmation >$230.40; weak <$224.75; invalid <$220.41. | $230.36, +0.84%; intraday high $234.76; low $229.63. | Near miss / still open Traded through the level but closed $0.04 below it. A close rule is not retroactively relaxed. | Monday confirmation becomes a hold above $229.63 and close above $234.76; below $224.75 still weakens. |
| HPE conditional bullish Hold $51.83–52.48; confirm >$54.88; invalid <$49.80. | $52.00, −4.48%; high $54.64; low $51.49. | Weakened, not invalidated Closed below $52.48 and did not clear $54.88; retained $49.80. | Downgraded from bullish to avoid/watch until it reclaims $54.64–54.88. |
| VRT conditional bullish Hold $261.79; confirm close >$270.99; invalid <$254.50. | $280.53, +4.35%; close near $280.99 high. | Confirmed Both hold and close-confirmation conditions met. | Trail rather than chase: $271.20 becomes first support; $268.83 close is deeper invalidation reference. |
| CIEN/AVGO/CRDO avoid-first Bearish only after listed breakdowns. | CIEN +1.12%, AVGO +0.21%, CRDO +3.90%; none closed below $311.60/$342.33/$161.95. | Avoid stance useful; shorts not triggered CRDO pierced $161.95 intraday but closed $170.57. | No short fill assumed. Remove CIEN/AVGO from ranked bearish ideas; CRDO remains watch-only while below event-damage resistance. |
| SNOW gap-hold watch Hold $355.47; below $350 weak; invalid <$319.25. | $337.18, −5.41%; low $337.11. | Weakness condition hit The gap-hold failed, though full invalidation did not. | Moves to avoid until it reclaims $356.83; no blind short after a two-day 20% range. |
| PLTR / IONQ / NVO watch | PLTR $174.33 (−4.49%) held $171.91; IONQ $39.52 (+1.28%) failed a $39.78 close; NVO $46.60 (−1.92%) failed $48. | No confirmations | All remain watch-only. No fill or win is claimed. |
Risk class: large-cap/high-beta AI power and cooling. Classification: confirmed momentum continuation, chase risk. Applicable horizons: day and 1–4 weeks; 3–12+ months only after valuation, backlog, margins and FCF review.
Thesis/catalyst: Friday's $280.53 close (+4.35%) confirmed the pre-stated $270.99 breakout despite a lower Nasdaq; AI infrastructure releases corroborate demand. Counterargument: volume 3.32M was below the roughly 4.02M trailing average, there was no fresh VRT primary catalyst, and price remains below the $300.30 20-session high.
Entry/confirmation: no gap chase; require $271.20 to hold and a close above $280.99, preferably with industrial/AI breadth. Invalidation/downside: close below $268.83 invalidates this continuation; $254.50 is deeper structural support. Key risks: valuation compression, capex timing, execution, competition, input costs, power/permitting, yields and gaps. price/volume · network demand
Risk class: mega-cap semiconductor with high expectations/M&A risk. Classification: near-breakout continuation. Applicable horizons: day and 1–4 weeks; 3–12+ months only after margins, FCF, valuation and acquisition review.
Thesis/catalyst: $230.36, +0.84%, outperformed Nasdaq and held above Thursday's $228.45 close; the intraday high extended to $234.76. Q2 revenue was $46.7B and Q3 guide $54.0B ±2%. Counterargument: it missed the $230.40 close rule by $0.04, volume was near rather than above its recent average, yields rose, and the announced Hugging Face acquisition adds integration/regulatory/capital-allocation risk.
Entry/confirmation: hold $229.63 and close above $234.76 with semiconductor breadth. Invalidation/downside: below $224.75 weakens; close below $220.41 invalidates. Key risks: margins, export controls/China, customer concentration, competition, M&A, power constraints, valuation and gaps. price · results · deal analysis
Risk class: large-cap cloud; extreme event, valuation and stock-compensation risk. Classification: avoid, not an automatic short. Applicable horizons: day and 1–4 weeks; no 3–12+ month bearish thesis without full FCF/SBC valuation work. Short loss can be unlimited.
Thesis/catalyst: Friday's $337.18 close (−5.41%) broke the pre-stated $350 weakness and $355.47 gap-hold levels after Thursday's +16.55% surge. Evidence/counterargument: the failed hold is objective, but product revenue +37%, RPO +30% and raised guidance support the business; event reversals and squeezes remain likely.
Entry/confirmation: avoid; tactical bearish only after a failed $350–356.83 reclaim and close below $337.11. Invalidation/downside: above $356.83 invalidates the bearish setup; prior long gap thesis fully fails only below $319.25. Key risks: squeeze/unlimited short loss, growth upside, GAAP losses/SBC, valuation, competition, consumption variability and gaps. Borrow/fees unknown. release · price
Risk class: large-cap infrastructure; integration/leverage and extreme event volatility. Classification: avoid until reclaim; no blind short. Applicable horizons: day and 1–4 weeks; 3–12+ months requires Juniper integration, margins, FCF and valuation analysis. Short loss unlimited.
Thesis/catalyst: $52.00, −4.48%, closed below the $52.48 hold level and could not clear $54.88. Evidence/counterargument: Friday weakened the technical breakout, but official Q3 revenue was $12.2B (+34%), data-center networking +112.2% and FY27 framework calls for at least $5B FCF.
Entry/confirmation: avoid; bearish only after a failed $52.48–54.64 reclaim and close below $51.49. Invalidation/downside: close above $54.88 cancels bearish framing; below $49.80 confirms larger failure. Key risks: squeeze, integration, debt, AI-server mix/margins, supply, concentration, competition and gaps. Borrow/fees unknown. official release · price
| Name / risk class | Classification & separately applicable horizon | Thesis, catalyst, evidence / counterargument | Entry / invalidation / key risks | C / R / O |
|---|---|---|---|---|
| Event watch ORCL · Oracle (NYSE) Mega-cap cloud; capex, debt and earnings-gap risk | Pre-earnings momentum. Day/1–4w: applicable through Sep. 10. 3–12m: only after backlog, cloud growth, capex, FCF and valuation review. Direction uncertain. | $158.78, +3.08%, 20-session high $159.70; Sep. 10 after-hours earnings is verified. Counter: event risk and third-party EPS forecast is not guidance. | No pre-event chase; confirm >$159.70 or wait for post-report range. Below $154.04 weakens; below $146.92 invalidates momentum. Risks: capex financing, execution, competition, rates/gap. calendar · price | 82 / 94 / 53 |
| Event watch ADBE · Adobe (Nasdaq) Large-cap software; earnings/transition risk | Damaged pre-event watch. Day/1–4w: only around Sep. 10 report. 3–12m: AI monetization, growth, FCF/valuation and succession review. Direction uncertain. | $266.51, −6.73% on 6.64M vs ~4.22M average; Sep. 10 report and Dec. 1 CEO transition verified. Counter: Friday drop may pre-discount concerns; no new fundamental deterioration was established. | Wait. Bullish only >$275.91; bearish only <$263.93 after failed reclaim. Above $292.88 invalidates bear; below $251.20 damages base. Risks: gap, competition, AI cannibalization, execution. Adobe · price | 85 / 96 / 48 |
| Speculative IONQ · IonQ (NYSE) Quantum; extreme duration/dilution volatility | Reclaim watch. Day/1–4w: only above trigger. 3–12m: requires commercial and unit-economic proof. Direction uncertain. | $39.52, +1.28%, but no $39.78 close; warrant dates verified. Counter: no fresh operating de-risking and below $41.92/$47.95 references. | Confirm close >$39.78, then $41.92. Below $38.83 weakens; below $36.785 invalidates. Risks: burn, dilution, architecture, long timelines, rates, gaps. 8-K · price | 83 / 99 / 45 |
| Peptide NVO · Novo Nordisk ADR (NYSE) Large-cap pharma; ADR/pipeline/pricing risk | Range watch. Day/1–4w: only above $46.74/$48. 3–12m: applicable after pipeline, reimbursement, manufacturing and valuation review. Direction uncertain. | $46.60, −1.92%; failed $48 trigger but held Friday close just above prior $46.57 reference. Counter: no new company catalyst; competition remains intense. | Confirm >$46.74 then $48. Below $46.04 weakens; below $44.68 invalidates rebound. Risks: pricing, supply, efficacy/safety, competition, FX/ADR. price | 65 / 78 / 46 |
| Small-cap biotech VKTX · Viking Therapeutics (Nasdaq) Small-cap peptide biotech; binary/financing risk | Momentum watch. Day/1–4w: technical only. 3–12m: requires full trial, safety, cash-runway, regulatory and competition review. Direction uncertain. | $34.87, +2.62%, near $34.95 high; no specific next-week primary catalyst verified. Counter: below $36.26 20-session high and clinical economics remain binary. | Confirm close >$34.95 then $36.26. Below $33.56 weakens; below $31.70 invalidates. Risks: endpoints/statistics, safety, timeline, runway/dilution, competition, manufacturing. price | 62 / 96 / 45 |
C/R/O = Thesis Confidence / Risk / Opportunity, 0–100; higher Risk is riskier. Confidence measures evidence quality—not guaranteed probability. No fill is assumed merely because an intraday level traded.
Bias: Monday U.S. cash is closed; on Tuesday, favor only VRT/NVDA continuation after opening-range confirmation. Do not chase ORCL into earnings or bottom-fish SNOW/HPE.
Biggest risk: holiday liquidity/geopolitical oil gap. Invalidation: constructive AI bias fails if VRT closes below $268.83 and NVDA below $224.75 while 10Y/oil rise.
Bias: neutral/selective. Keep position size smaller into ORCL/ADBE, CPI and FOMC. Quantum and peptide names remain watch-only absent operating/clinical proof.
Biggest risk: CPI validates an inflation/rate-hike regime. Invalidation: S&P close below Friday's 7,706.12 low with VIX above 15.44 and 10Y above 4.78% would turn neutral toward risk-off.
Bias: favor profitable AI infrastructure only after valuation, FCF, debt and concentration review; demand commercial unit economics in quantum and endpoint/safety/runway evidence in biotech.
Biggest risk: sustained high rates/oil plus AI capex digestion, dilution or clinical failure. Invalidation: durable order, margin and FCF deterioration—not a single session—would challenge the long AI-infrastructure thesis.